Vistagen Therapeutics Files 8-K
Ticker: VTGN · Form: 8-K · Filed: Feb 5, 2025 · CIK: 1411685
| Field | Detail |
|---|---|
| Company | Vistagen Therapeutics, Inc. (VTGN) |
| Form Type | 8-K |
| Filed Date | Feb 5, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, financials
Related Tickers: VTGN
TL;DR
VTGN filed an 8-K on Feb 5, 2025, mostly for financial docs. No major news yet.
AI Summary
On February 5, 2025, Vistagen Therapeutics, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific material events detailed in the provided text. The company is incorporated in Nevada and headquartered in South San Francisco, California.
Why It Matters
This 8-K filing indicates Vistagen Therapeutics is providing updates on its financial statements and exhibits, which could contain important information for investors regarding the company's financial health and operational status.
Risk Assessment
Risk Level: low — The provided text is a standard 8-K filing notification and does not contain specific material events or financial disclosures that would indicate a change in risk.
Key Players & Entities
- Vistagen Therapeutics, Inc. (company) — Registrant
- February 5, 2025 (date) — Date of Report
- Nevada (jurisdiction) — State of Incorporation
- South San Francisco, California (location) — Principal Executive Offices
- 650-577-3600 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing by Vistagen Therapeutics?
The primary purpose of this 8-K filing is to report on 'Other Events' and to provide 'Financial Statements and Exhibits'.
When was this 8-K report filed?
This 8-K report was filed on February 5, 2025.
In which state is Vistagen Therapeutics, Inc. incorporated?
Vistagen Therapeutics, Inc. is incorporated in Nevada.
What is the address of Vistagen Therapeutics' principal executive offices?
The address of Vistagen Therapeutics' principal executive offices is 343 Allerton Ave., South San Francisco, California 94080.
Does the filing specify any new material events or agreements?
The provided text of the filing does not specify any new material events or agreements; it primarily indicates the filing of financial statements and exhibits.
Filing Stats: 493 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2025-02-05 17:04:59
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share VTGN Nasdaq Capital Market
Filing Documents
- vtgn-20250205.htm (8-K) — 24KB
- ex991-avx101nppatentpr2025.htm (EX-99.1) — 21KB
- image.jpg (GRAPHIC) — 12KB
- 0001411685-25-000011.txt ( ) — 188KB
- vtgn-20250205.xsd (EX-101.SCH) — 2KB
- vtgn-20250205_lab.xml (EX-101.LAB) — 21KB
- vtgn-20250205_pre.xml (EX-101.PRE) — 12KB
- vtgn-20250205_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events On February 5, 2025, Vistagen Therapeutics, Inc. (the " Company ") issued a press release to announce that the U.S. Patent and Trademark Office granted a patent to the Company for its oral non-opioid product candidate, AV-101, for the treatment of neuropathic pain. The patent will not expire until at least 2034 and is part of the Company's global patent portfolio on manufacturing methods and therapeutic uses for AV-101 to treat various disorders involving the NMDA receptor. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Index Exhibit No. Description 99.1 Press Release issued by Vistagen Therapeutics, Inc., dated February 5, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
Signatures
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Vistagen Therapeutics, Inc. Date: February 5, 2025 By: /s/ Shawn K. Singh Shawn K. Singh President and Chief Executive Officer